Figure 2From: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury Updated meta-analysis of effect of Bradykinin B2 receptor antagonists on mortality after traumatic brain injury.Back to article page